Abstract P4-06-03: Clinical-risk assessment of ER positive, Her2 negative breast cancer patients: Correlation between the average modified magee score and mammaprint
Authors: Hani Katerji, Huina Zhang, David Hicks, Bradley M Turner
Journal: Cancer Research (2022)

Abstract Background: MammaPrint (MP) is an FDA approved early breast cancer prognostic genomic assay that examines the expression levels of 70 genes and classifies clinically high-risk patients with early-stage breast cancer into low or high risk of distant metastasis. Current ASCO guidelines do not support using MP testing in clinically low-risk patients. Historically, assessing a patient’s clinical risk for breast cancer recurrence has relied on a subjective evaluation of histologic factors, immunohistochemical features, and clinical characteristics. Genomic assay testing provides more objective prognostic and predictive information than those more traditional methods; however, several studies have shown that statistical models using standard histologic variables can give valuable prognostic information, and might be used as an alternative approach to genomic assays for clinical risk-assessment and risk-stratification, particularly in lower risk breast cancer patients, potentially resulting in significant cost savings for health care systems. One of these statistical models, the average Modified Magee equation, has been shown to be prognostic for a low risk of recurrence in ER positive Her2 negative breast cancer patients who have an average Modified Magee score (aMMs) of ≤ 12. The aMMs has been shown to correlate well with the Oncotype DX recurrence score; however, there is limited data on the correlation between the aMMs and MP. In this study, we evaluated the concordance between the aMMs and the MP index (MPI). Methods: 222 consecutive patients with a new diagnosis of hormone receptor positive Her-2 negative breast cancer at the University of Rochester between April 2020 and December 2020 were sent for MP testing. The aMMs was determined for each patient based on the estrogen receptor status, progesterone receptor status, HER-2 status, Ki-67 proliferation index, Nottingham score, and tumor size. Based on the previous literature, patients were risk-stratified by the aMMs into three groups: 1) low risk (aMMs ≤ 12; n = 75); 2) low - intermediate risk (aMMs &amp;gt;12 and ≤ 18; n = 96); and, 3) high risk (aMMs &amp;gt;18, n = 51). Based on the previous literature, patients were risk-stratified by the MPI into two groups: 1) low risk (MPI 0 to +1); and, 2) high risk (MPI -1 to 0). The correlation between the aMMs and the MPI was evaluated using the Pearson correlation coefficient. Results: The aMMs showed a negative correlation (r= -0.55) with the MPI, consistent with a lower risk aMMs more likely being associated with a lower risk MPI. 92% of patients with an aMMs ≤ 12 (very low risk) were classified as low risk by MP. 72% of patients with an aMMs &amp;gt; 12 and ≤ 18 (low - intermediate risk) were classified as low risk by MP. 47% of patients with an aMMs &amp;gt; 18 (high risk) were classified as high risk by MP (Table 1). All patients with an aMMs ≥ 24.7 (n=8) were classified as high risk by MP. Conclusion: Our study suggests that hormone receptor positive, Her-2 negative breast cancer patients with a lower risk aMMs are likely to have a lower MPI, suggesting that these patients have a decreased risk for breast cancer recurrence. As the aMMs approaches higher risk, the concordance with the MPI decreases; however 100% of patients with an aMMs ≥ 24.7 were classified as high risk by MP. The aMMs can be helpful in clinical risk-assessment prior to making a decision about sending a patient specimen out for MP testing. Additional studies are warranted. Table 1.Risk of recurrence using the average Modified Magee score (aMMs) and the MammaPrint (MP) IndexaMMs Risk-stratification categoryMP Low risk n (%)MP High risk n (%)Very low (aMMs ≤ 12)69 (92%)6 (8%)Low - Intermediate (aMMs &amp;gt; 12 and ≤ 18)69 (72%)27 (28%)High (aMMs &amp;gt;18)27 (53%)24 (47%) Citation Format: Hani Katerji, Huina Zhang, David Hicks, Bradley M Turner. Clinical-risk assessment of ER positive, Her2 negative breast cancer patients: Correlation between the average modified magee score and mammaprint [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P4-06-03.